Development of the vaccine of coronavirus
'%20x='0'%20y='0'%20height='100%25'%20width='100%25'%20xlink%3Ahref='data%3Aimage/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDABALDA4MChAODQ4SERATGCgaGBYWGDEjJR0oOjM9PDkzODdASFxOQERXRTc4UG1RV19iZ2hnPk1xeXBkeFxlZ2P/2wBDARESEhgVGC8aGi9jQjhCY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2P/wAARCAAGAAkDASIAAhEBAxEB/8QAFgABAQEAAAAAAAAAAAAAAAAAAAQF/8QAHhAAAAYCAwAAAAAAAAAAAAAAAAECAwQSERRjgZH/xAAUAQEAAAAAAAAAAAAAAAAAAAAC/8QAFhEBAQEAAAAAAAAAAAAAAAAAAQIA/9oADAMBAAIRAxEAPwCuHCJpNm3EpbNV6k0RZ7yM/Yk8XgADN1ghv//Z'%3E%3C/image%3E%3C/svg%3E)
In Key Breakthrough, Covid-19 Vaccine Developed by Oxford University Scientist Could Be Available Around October Sarah Gilbert, a professor of vaccinology, said efficacy result from phase 3 trials of the vaccine will be available by autumn of 2020 but cautioned these best-case time frames are highly ambitious. UPDATED ON: APRIL 18, 2020, 3:33 PM IST News18.com Image for representation. (REUTERS/Andreas Gebert) A vaccine trial for Covid-19 at the University of Oxford seeks to administer the shot to 500 participants by May, Sarah Gilbert, a professor of vaccinology at the university, has told The Lancet. Individuals aged between 18 to 55 years are being enrolled in the early- and mid-stage randomized, controlled trial, Bloomberg reported. Advertisement “The best-case scenario is that by the autumn of 2020, we have an efficacy result from phase 3 and the ability to manufacture large amounts of the vaccine, but these best-case time frames are highly ambitious and subject t
